Lipid disorders before and after successful liver transplantation

  • Damian Gojowy Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland https://orcid.org/0000-0003-4916-2863
  • Joanna Urbaniec-Stompór Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Joanna Adamusik Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Gabriela Wójcik Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Henryk Karkoszka Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Robert Król Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland
  • Andrzej Więcek Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Marcin Adamczak Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Abstract

Introduction: Liver transplantation (LTx) is the only successful treatment for end-stage liver disease. The results of liver transplantation depend not only on graft survival but may be also affected by superimposed cardiovascular morbidities. The aim of this retrospective study was to assess the prevalence of lipid disorders as one of the important cardiovascular risk factors in patients before and after successful LTx. Material and Methods: One hundred eleven patients who underwent liver transplantation because of liver cirrhosis and survived at least 2 years with functioning graft between November 2005 and May 2014 were included in this retrospective analysis. The mean age of the patients at the time of liver transplantation was 49.7±12.2 years. The prevalence of dyslipidemia was assessed before and two years after liver transplantation. This was analyzed in relation to the etiology of liver disease, including alcohol toxicity, viral or autoimmune diseases. Results: The prevalence of hypertriglyceridemia before and after LTx was 13.5% and 40.5%, respectively (P<0.001). Similarly, hypercholesterolemia was noted in 17.1% and 51.4% respectively (P<0.001). The annual incidence of hypertriglyceridemia and hypercholesterolemia during the first two years after LTx was 16.2% and 20.7%, respectively. The prevalence of hypertriglyceridemia (18.5% vs 66.7%, P<0.001) and hypercholesterolemia (29.6% vs 70.0%, P=0.002) was significantly lower in patients with the autoimmune cause of liver cirrhosis in comparison to patients with the alcoholic liver disease. Conclusions: The prevalence of dyslipidemia is increased after liver transplantation. The prevalence of dyslipidemia may be related to the cause of liver injury before LTx.

Published
2023-12-03
Section
Articles